BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions...…
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…
Atea reported very strong sales in all countries and across all lines of business during the fourth quarter, driving record…
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…
Atea ASA will present its 4[th] quarter 2022 financial results on Thursday, 9 February 2023 at 08:00 CEST.
The presentation will…
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…
Oslo, 30 December
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Oslo, 22 December
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Oslo, 21 December 2022 — Atea today announced that the company has earned a Leadership Band placement among global companies analyzed by…
Oslo, 15 December
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Oslo, 8 December
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Oslo, 1 December
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Oslo, 24 November
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…
Oslo, 17 November
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings…
Oslo, 10 November
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…
Oslo, 3 November
Please see below information about transactions made under the share buyback programme for Atea ASA.
Date on which the…
Initiation of share repurchase program
The Board of Directors of Atea ASA has resolved to initiate a share repurchase program. The…
Atea reported exceptionally strong organic growth, higher EBIT, and very positive cash flow from operations in the third quarter of…
The Board of Atea ASA has proposed a cash dividend with the following key details:
Dividend amount: …
Atea ASA will present its 3[rd] quarter 2022 financial results on Thursday, 20 October 2022 at 08:00 CEST.
The presentation will…